메뉴 건너뛰기




Volumn 119, Issue 4, 2012, Pages 1008-1017

Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents

Author keywords

[No Author keywords available]

Indexed keywords

6 (1,3 DIOXO 1H,3H BENZO[DE]ISOQUINOLIN 2 YL) N HYDROXYHEXANAMIDE; ANTIVIRUS AGENT; APICIDIN; BELINOSTAT; BUTYRIC ACID; ENTINOSTAT; GANCICLOVIR; HISTONE DEACETYLASE INHIBITOR; LARGAZOLE; OXAMFLATIN; PANOBINOSTAT; THYMIDINE KINASE; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT;

EID: 84863039812     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-06-362434     Document Type: Article
Times cited : (139)

References (48)
  • 1
    • 0027506845 scopus 로고
    • Epstein-Barr virus infections: Biology, pathogenesis, and management
    • NIH conference
    • Straus SE, Cohen JI, Tosato G, Meier J. NIH conference. Epstein-Barr virus infections: biology, pathogenesis, and management. Ann Intern Med. 1993;118(1):45-58.
    • (1993) Ann Intern Med , vol.118 , Issue.1 , pp. 45-58
    • Straus, S.E.1    Cohen, J.I.2    Tosato, G.3    Meier, J.4
  • 2
    • 49749222804 scopus 로고
    • Virus particles in cultured lymphoblasts from Burkitt's lymphoma
    • Epstein M, Achong B, Barr Y. Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet. 1964;1:702-703.
    • (1964) Lancet , vol.1 , pp. 702-703
    • Epstein, M.1    Achong, B.2    Barr, Y.3
  • 3
    • 0028355939 scopus 로고
    • Nasopharyngeal carcinoma: The Epstein-Barr virus association
    • Liebowitz D. Nasopharyngeal carcinoma: the Epstein-Barr virus association. Semin Oncol. 1994;21(3):376-381. (Pubitemid 24191597)
    • (1994) Seminars in Oncology , vol.21 , Issue.3 , pp. 376-381
    • Liebowitz, D.1
  • 4
    • 0034070035 scopus 로고    scopus 로고
    • The role of EBV in post-transplant malignancies: A review
    • DOI 10.1136/jcp.53.4.248
    • Hopwood P, Crawford DH. The role of EBV in post-transplant malignancies: a review. J Clin Pathol. 2000;53(4):248-254. (Pubitemid 30180395)
    • (2000) Journal of Clinical Pathology , vol.53 , Issue.4 , pp. 248-254
    • Hopwood, P.1    Crawford, D.H.2
  • 6
    • 0027479343 scopus 로고
    • Epstein-Barr virus-associated non-Hodgkin's lymphoma in patients infected with the human immunodeficiency virus
    • Shibata D,Weiss LM, Hernandez AM, Nathwani BN, Bernstein L, Levine AM. Epstein-Barr virusassociated non-Hodgkin's lymphoma in patients infected with the human immunodeficiency virus. Blood. 1993;81(8):2102-2109. (Pubitemid 23106725)
    • (1993) Blood , vol.81 , Issue.8 , pp. 2102-2109
    • Shibata, D.1    Weiss, L.M.2    Hernandez, A.M.3    Nathwani, B.N.4    Bernstein, L.5    Levine, A.M.6
  • 9
    • 0030067422 scopus 로고    scopus 로고
    • Switching viral latency to viral lysis: A novel therapeutic approach for Epstein-Barr virus-associated neoplasia
    • Gutiérrez MI, Judde JG, Magrath IT, Bhatia KG. Switching viral latency to viral lysis: a novel therapeutic approach for Epstein-Barr virus-associated neoplasia. Cancer Res. 1996;56(5):969-972. (Pubitemid 26065387)
    • (1996) Cancer Research , vol.56 , Issue.5 , pp. 969-972
    • Gutierrez, M.I.1    Judde, J.G.2    Magrath, I.T.3    Bhatia, K.G.4
  • 10
    • 0034870826 scopus 로고    scopus 로고
    • Epstein-Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: Pharmacological re-activation of viral target genes with arginine butyrate
    • DOI 10.1034/j.1399-3062.2001.003003177.x
    • Mentzer SJ, Perrine SP, Faller DV. Epstein-Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: pharmacological reactivation of viral target genes with arginine butyrate. Transpl Infect Dis. 2001;3(3):177-185. (Pubitemid 32756700)
    • (2001) Transplant Infectious Disease , vol.3 , Issue.3 , pp. 177-185
    • Mentzer, S.J.1    Perrine, S.P.2    Faller, D.V.3
  • 11
    • 0041465971 scopus 로고    scopus 로고
    • Virally targeted therapies for EBV-associated malignancies
    • DOI 10.1038/sj.onc.1206548
    • Israel BF, Kenney SC. Virally targeted therapies for EBV-associated malignancies. Oncogene. 2003;22(33):5122-5130. (Pubitemid 37059593)
    • (2003) Oncogene , vol.22 , Issue.33 REV. ISS. 2 , pp. 5122-5130
    • Israel, B.F.1    Kenney, S.C.2
  • 12
    • 0032104738 scopus 로고    scopus 로고
    • Arginine butyrate-induced susceptibility to ganciclovir in an Epstein-Barr-virus-associated lymphoma
    • DOI 10.1006/bcmd.1998.0178
    • Mentzer SJ, Fingeroth J, Reilly JJ, Perrine SP, Faller DV. Arginine butyrate-induced susceptibility to ganciclovir in an Epstein-Barr-virus- associated lymphoma. Blood Cells Mol Dis. 1998;24(2):114-123. (Pubitemid 28365731)
    • (1998) Blood Cells, Molecules and Diseases , vol.24 , Issue.2 , pp. 114-123
    • Mentzer, S.J.1    Fingeroth, J.2    Reilly, J.J.3    Perrine, S.P.4    Faller, D.V.5
  • 13
    • 0034667460 scopus 로고    scopus 로고
    • Activation of lytic Epstein-Barr virus (EBV) infection by radiation and sodium butyrate in vitro and in vivo: A potential method for treating EBV-positive malignancies
    • Westphal EM, Blackstock W, Feng W, Israel B, Kenney SC. Activation of lytic Epstein-Barr virus (EBV) infection by radiation and sodium butyrate in vitro and in vivo: a potential method for treating EBV-positive malignancies. Cancer Res. 2000; 60(20):5781-5788.
    • (2000) Cancer Res , vol.60 , Issue.20 , pp. 5781-5788
    • Westphal, E.M.1    Blackstock, W.2    Feng, W.3    Israel, B.4    Kenney, S.C.5
  • 14
    • 0034954624 scopus 로고    scopus 로고
    • Induction of Epstein-Barr virus kinases to sensitize tumor cells to nucleoside analogues
    • DOI 10.1128/AAC.45.7.2082-2091.2001
    • Moore SM, Cannon JS, Tanhehco YC, Hamzeh FM, Ambinder RF. Induction of Epstein-Barr virus kinases to sensitize tumor cells to nucleoside analogues. Antimicrob Agents Chemother. 2001; 45(7):2082-2091. (Pubitemid 32591702)
    • (2001) Antimicrobial Agents and Chemotherapy , vol.45 , Issue.7 , pp. 2082-2091
    • Moore, S.M.1    Cannon, J.S.2    Tanhehco, Y.C.3    Hamzeh, F.M.4    Ambinder, R.F.5
  • 15
    • 17444411923 scopus 로고    scopus 로고
    • Induction of lytic Epstein-Barr virus (EBV) infection by synergistic action of rituximab and dexamethasone renders EBV-positive lymphoma cells more susceptible to ganciclovir cytotoxicity in vitro and in vivo
    • DOI 10.1128/JVI.79.9.5875-5879.2005
    • Daibata M, Bandobashi K, Kuroda M, Imai S, Miyoshi I, Taguchi H. Induction of lytic Epstein-Barr virus (EBV) infection by synergistic action of rituximab and dexamethasone renders EBV-positive lymphoma cells more susceptible to ganciclovir cytotoxicity in vitro and in vivo. J Virol. 2005;79(9):5875- 5879. (Pubitemid 40548258)
    • (2005) Journal of Virology , vol.79 , Issue.9 , pp. 5875-5879
    • Daibata, M.1    Bandobashi, K.2    Kuroda, M.3    Imai, S.4    Miyoshi, I.5    Taguchi, H.6
  • 16
    • 0842326026 scopus 로고    scopus 로고
    • Lytic Induction Therapy for Epstein-Barr Virus-Positive B-Cell Lymphomas
    • DOI 10.1128/JVI.78.4.1893-1902.2004
    • Feng WH, Hong G, Delecluse HJ, Kenney SC.Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas. J Virol. 2004;78(4): 1893-1902. (Pubitemid 38176721)
    • (2004) Journal of Virology , vol.78 , Issue.4 , pp. 1893-1902
    • Feng, W.-H.1    Hong, G.2    Delecluse, H.-J.3    Kenney, S.C.4
  • 17
    • 53549087773 scopus 로고    scopus 로고
    • Bortezomib-induced enzyme-targeted radiation therapy in herpesvirus-associated tumors
    • Fu DX, Tanhehco Y, Chen J, et al. Bortezomib-induced enzyme-targeted radiation therapy in herpesvirus-associated tumors. Nat Med. 2008; 14(10):1118-1122.
    • (2008) Nat Med , vol.14 , Issue.10 , pp. 1118-1122
    • Fu, D.X.1    Tanhehco, Y.2    Chen, J.3
  • 19
    • 0035063182 scopus 로고    scopus 로고
    • Transcriptional control at regulatory checkpoints by histone deacetylases: Molecular connections between cancer and chromatin
    • Wade PA. Transcriptional control at regulatory checkpoints by histone deacetylases: molecular connections between cancer and chromatin. Hum Mol Genet. 2001;10(7):693-698. (Pubitemid 32331577)
    • (2001) Human Molecular Genetics , vol.10 , Issue.7 , pp. 693-698
    • Wade, P.A.1
  • 20
    • 0035724413 scopus 로고    scopus 로고
    • The SMRT and N-CoR corepressors are activating cofactors for histone deacetylase 3
    • DOI 10.1128/MCB.21.18.6091-6101.2001
    • Guenther MG, Barak O, Lazar MA. The SMRT and N-CoR corepressors are activating cofactors for histone deacetylase 3. Mol Cell Biol. 2001; 21(18):6091-6101. (Pubitemid 34263509)
    • (2001) Molecular and Cellular Biology , vol.21 , Issue.18 , pp. 6091-6101
    • Guenther, M.G.1    Barak, O.2    Lazar, M.A.3
  • 22
    • 4143140016 scopus 로고    scopus 로고
    • Histone deacetylase inhibitors open new doors in cancer therapy
    • DOI 10.1016/j.bcp.2004.05.034, PII S0006295204003697
    • McLaughlin F, La Thangue NB. Histone deacetylase inhibitors open new doors in cancer therapy. Biochem Pharmacol. 2004;68(6):1139-1144. (Pubitemid 39094279)
    • (2004) Biochemical Pharmacology , vol.68 , Issue.6 , pp. 1139-1144
    • McLaughlin, F.1    La, T.N.B.2
  • 23
    • 77649171884 scopus 로고    scopus 로고
    • Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents
    • Tan J, Cang S, Ma Y, Petrillo RL, Liu D. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol. 2010;3:5.
    • (2010) J Hematol Oncol , vol.3 , pp. 5
    • Tan, J.1    Cang, S.2    Ma, Y.3    Petrillo, R.L.4    Liu, D.5
  • 24
    • 67449127082 scopus 로고    scopus 로고
    • Clinical studies of histone deacetylase inhibitors
    • Prince HM, Bishton MJ, Harrison SJ. Clinical studies of histone deacetylase inhibitors. Clin Cancer Res. 2009;15(12):3958-3969.
    • (2009) Clin Cancer Res , vol.15 , Issue.12 , pp. 3958-3969
    • Prince, H.M.1    Bishton, M.J.2    Harrison, S.J.3
  • 25
    • 36148950997 scopus 로고    scopus 로고
    • FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma
    • DOI 10.1634/theoncologist.12-10-1247
    • Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist. 2007;12(10):1247-1252. (Pubitemid 350106355)
    • (2007) Oncologist , vol.12 , Issue.10 , pp. 1247-1252
    • Mann, B.S.1    Johnson, J.R.2    Cohen, M.H.3    Justice, R.4    Pazdur, R.5
  • 26
    • 77954884940 scopus 로고    scopus 로고
    • Romidepsin: A new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors
    • Grant C, Rahman F, Piekarz R, et al. Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors. Expert Rev Anticancer Ther. 2010;10(7):997-1008.
    • (2010) Expert Rev Anticancer Ther , vol.10 , Issue.7 , pp. 997-1008
    • Grant, C.1    Rahman, F.2    Piekarz, R.3
  • 27
    • 0014139019 scopus 로고
    • Immunofluorescence and herpes-type virus particles in the P3HR-1 Burkitt lymphoma cell line
    • Hinuma Y, Konn M, Yamaguchi J, Wudarski DJ, Blakeslee JR Jr, Grace JT Jr. Immunofluorescence and herpes-type virus particles in the P3HR-1 Burkitt lymphoma cell line. J Virol. 1967; 1(5):1045-1051.
    • (1967) J Virol , vol.1 , Issue.5 , pp. 1045-1051
    • Hinuma, Y.1    Konn, M.2    Yamaguchi, J.3    Wudarski, D.J.4    Blakeslee Jr., J.R.5    Grace Jr., J.T.6
  • 28
    • 0014304475 scopus 로고
    • Surface IgM-kappa specificity on a Burkitt lymphoma cell in vivo and in derived culture lines
    • Klein E, Klein G, Nadkarni JS, Nadkarni JJ, Wigzell H, Clifford P. Surface IgM-kappa specificity on a Burkitt lymphoma cell in vivo and in derived culture lines. Cancer Res. 1968;28(7): 1300-1310.
    • (1968) Cancer Res , vol.28 , Issue.7 , pp. 1300-1310
    • Klein, E.1    Klein, G.2    Nadkarni, J.S.3    Nadkarni, J.J.4    Wigzell, H.5    Clifford, P.6
  • 29
    • 0017237293 scopus 로고
    • Structure of HLA antigens: Amino-acid and carbohydrate compositions and NH2-terminal sequences of four antigen preparations
    • Terhorst C, Parham P, Mann DL, Strominger JL. Structure of HLA antigens: amino-acid and carbohydrate compositions and NH2-terminal sequences of four antigen preparations. Proc Natl Acad Sci U S A. 1976;73(3):910-914.
    • (1976) Proc Natl Acad Sci U S A , vol.73 , Issue.3 , pp. 910-914
    • Terhorst, C.1    Parham, P.2    Mann, D.L.3    Strominger, J.L.4
  • 30
    • 0016835245 scopus 로고
    • Establishment and characterization of an Epstein-Barr virus (EBC)-negative lymphoblastoid B cell line (BJA-B) from an exceptional, EBV-genome-negative African Burkitt's lymphoma
    • Menezes J, Leibold W, Klein G, Clements G. Establishment and characterization of an Epstein-Barr virus (EBC)-negative lymphoblastoid B cell line (BJA-B) from an exceptional, EBV-genome-negative African Burkitt's lymphoma. Biomedicine. 1975;22(4):276-284.
    • (1975) Biomedicine , vol.22 , Issue.4 , pp. 276-284
    • Menezes, J.1    Leibold, W.2    Klein, G.3    Clements, G.4
  • 31
    • 0032818721 scopus 로고    scopus 로고
    • Somatic mutations and intraclonal variations in the rearranged V(K) genes of B-non-Hodgkin's lymphoma cell lines
    • Gabay C, Ben-Bassat H, Schlesinger M, Laskov R. Somatic mutations and intraclonal variations in the rearranged Vkappa genes of B-non-Hodgkin's lymphoma cell lines. Eur J Haematol. 1999;63(3): 180-191. (Pubitemid 29406735)
    • (1999) European Journal of Haematology , vol.63 , Issue.3 , pp. 180-191
    • Gabay, C.1    Ben-Bassat, H.2    Schlesinger, M.3    Laskov, R.4
  • 32
    • 64049106355 scopus 로고    scopus 로고
    • Synthesis and histone deacetylase inhibitory activity of largazole analogs: Alteration of the zinc-binding domain and macrocyclic scaffold
    • Bowers AA, West N, Newkirk TL, et al. Synthesis and histone deacetylase inhibitory activity of largazole analogs: alteration of the zinc-binding domain and macrocyclic scaffold. Org Lett. 2009; 11(6):1301-1304.
    • (2009) Org Lett , vol.11 , Issue.6 , pp. 1301-1304
    • Bowers, A.A.1    West, N.2    Newkirk, T.L.3
  • 33
    • 33845599154 scopus 로고    scopus 로고
    • Short, discontinuous exposure to butyrate effectively sensitizes latently EBV-infected lymphoma cells to nucleoside analogue antiviral agents
    • DOI 10.1016/j.bcmd.2006.10.008, PII S1079979606002336
    • Ghosh SK, Forman LW, Akinsheye I, Perrine SP, Faller DV. Short, discontinuous exposure to butyrate effectively sensitizes latently EBV-infected lymphoma cells to nucleoside analogue antiviral agents. Blood Cells Mol Dis. 2007;38(1):57-65. (Pubitemid 44960868)
    • (2007) Blood Cells, Molecules, and Diseases , vol.38 , Issue.1 , pp. 57-65
    • Ghosh, S.K.1    Forman, L.W.2    Akinsheye, I.3    Perrine, S.P.4    Faller, D.V.5
  • 34
    • 46049100010 scopus 로고    scopus 로고
    • Total synthesis and molecular target of largazole, a histone deacetylase inhibitor
    • DOI 10.1021/ja8013727
    • Ying Y, Taori K, Kim H, Hong J, Luesch H. Total synthesis and molecular target of largazole, a histone deacetylase inhibitor. J Am Chem Soc. 2008;130(26):8455-8459. (Pubitemid 351898566)
    • (2008) Journal of the American Chemical Society , vol.130 , Issue.26 , pp. 8455-8459
    • Ying, Y.1    Taori, K.2    Kim, H.3    Hong, J.4    Luesch, H.5
  • 35
    • 0020683890 scopus 로고
    • Effect of arabinofuranosylthymine on the replication of Epstein-Barr virus and relationship with a new induced thymidine kinase activity
    • Ooka T, Calender A, de Turenne M, Daillie J. Effect of arabinofuranosylthymine on the replication of Epstein-Barr virus and relationship with a new induced thymidine kinase activity. J Virol. 1983;46(1):187-195. (Pubitemid 13161258)
    • (1983) Journal of Virology , vol.46 , Issue.1 , pp. 187-195
    • Ooka, T.1    Calender, A.2    De Turenne, M.3    Daillie, J.4
  • 36
    • 77950850768 scopus 로고    scopus 로고
    • The Epstein-Barr virus (EBV)-encoded protein kinase, EBV-PK, but not the thymidine kinase (EBV-TK), is required for ganciclovir and acyclovir inhibition of lytic viral production
    • Meng Q, Hagemeier SR, Fingeroth JD, Gershburg E, Pagano JS, Kenney SC. The Epstein-Barr virus (EBV)-encoded protein kinase, EBV-PK, but not the thymidine kinase (EBV-TK), is required for ganciclovir and acyclovir inhibition of lytic viral production. J Virol. 2010;84(9):4534-4542.
    • (2010) J Virol , vol.84 , Issue.9 , pp. 4534-4542
    • Meng, Q.1    Hagemeier, S.R.2    Fingeroth, J.D.3    Gershburg, E.4    Pagano, J.S.5    Kenney, S.C.6
  • 37
    • 33744484523 scopus 로고    scopus 로고
    • Epstein-Barr virus (EBV) and its associated human cancers - Genetics, epigenetics, pathobiology and novel therapeutics
    • DOI 10.2741/2000
    • Tao Q, Young LS, Woodman CB, Murray PG. Epstein-Barr virus (EBV) and its associated human cancers - genetics, epigenetics, pathobiology and novel therapeutics. Front Biosci. 2006;11: 2672-2713. (Pubitemid 43806572)
    • (2006) Frontiers in Bioscience , vol.11 , Issue.SUPPL. 2 , pp. 2672-2713
    • Tao, Q.1    Young, L.S.2    Woodman, C.B.J.3    Murray, P.G.4
  • 38
    • 0031724984 scopus 로고    scopus 로고
    • The Epstein-Barr virus thymidine kinase does not phosphorylate ganciclovir or acyclovir and demonstrates a narrow substrate specificity compared to the herpes simplex virus type 1 thymidine kinase
    • Gustafson EA, Chillemi AC, Sage DR, Fingeroth JD. The Epstein-Barr virus thymidine kinase does not phosphorylate ganciclovir or acyclovir and demonstrates a narrow substrate specificity compared to the herpes simplex virus type 1 thymidine kinase. Antimicrob Agents Chemother. 1998; 42(11):2923-2931. (Pubitemid 28501227)
    • (1998) Antimicrobial Agents and Chemotherapy , vol.42 , Issue.11 , pp. 2923-2931
    • Gustafson, E.A.1    Chillemi, A.C.2    Sage, D.R.3    Fingeroth, J.D.4
  • 39
    • 84863078906 scopus 로고    scopus 로고
    • Short-term exposure to arginine butyrate, in combination with ganciclovir, is as effective as continuous exposure for virus-targeted therapy of EBV-positive lymphomas
    • [abstract]
    • Faller DV, Ghosh S, Feldman T, et al. Short-term exposure to arginine butyrate, in combination with ganciclovir, is as effective as continuous exposure for virus-targeted therapy of EBV-positive lymphomas [abstract]. Blood. 2009;114(1):4754.
    • (2009) Blood , vol.114 , Issue.1 , pp. 4754
    • Faller, D.V.1    Ghosh, S.2    Feldman, T.3
  • 41
    • 34447101115 scopus 로고    scopus 로고
    • MS-275, a potent orally available inhibitor of histone deacetylases-The development of an anticancer agent
    • DOI 10.1016/j.biocel.2007.02.009, PII S135727250700057X
    • Hess-Stumpp H, Bracker TU, Henderson D, Politz O. MS-275, a potent orally available inhibitor of histone deacetylases - the development of an anticancer agent. Int J Biochem Cell Biol. 2007;39(7-8):1388-1405. (Pubitemid 47031032)
    • (2007) International Journal of Biochemistry and Cell Biology , vol.39 , Issue.7-8 , pp. 1388-1405
    • Hess-Stumpp, H.1    Bracker, T.U.2    Henderson, D.3    Politz, O.4
  • 42
    • 77951884767 scopus 로고    scopus 로고
    • A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castrationresistant prostate cancer
    • Rathkopf D, Wong BY, Ross RW, et al. A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castrationresistant prostate cancer. Cancer Chemother Pharmacol. 2010;66(1):181-189.
    • (2010) Cancer Chemother Pharmacol , vol.66 , Issue.1 , pp. 181-189
    • Rathkopf, D.1    Wong, B.Y.2    Ross, R.W.3
  • 43
    • 0023235414 scopus 로고
    • Epstein-Barr virus gene expression in P3HR1-superinfected Raji cells
    • Biggin M, Bodescot M, Perricaudet M, Farrell P. Epstein-Barr virus gene expression in P3HR1-superinfected Raji cells. J Virol. 1987;61(10): 3120-3132. (Pubitemid 17131493)
    • (1987) Journal of Virology , vol.61 , Issue.10 , pp. 3120-3132
    • Biggin, M.1    Bodescot, M.2    Perricaudet, M.3    Farrell, P.4
  • 44
    • 0021415065 scopus 로고
    • The EB virus genome in Daudi Burkitt's lymphoma cells has a deletion similar to that observed in a non-transforming strain (P3HR-1) of the virus
    • Jones MD, Foster L, Sheedy T, Griffin BE. The EB virus genome in Daudi Burkitt's lymphoma cells has a deletion similar to that observed in a non-transforming strain (P3HR-1) of the virus. EMBO J. 1984;3(4):813-821.
    • (1984) EMBO J , vol.3 , Issue.4 , pp. 813-821
    • Jones, M.D.1    Foster, L.2    Sheedy, T.3    Griffin, B.E.4
  • 45
    • 43049119236 scopus 로고    scopus 로고
    • The use of diversity profiling to characterize chemical modulators of the histone deacetylases
    • Blackwell L, Norris J, Suto CM, Janzen WP. The use of diversity profiling to characterize chemical modulators of the histone deacetylases. Life Sci. 2008;82(21-22):1050-1058.
    • (2008) Life Sci , vol.82 , Issue.21-22 , pp. 1050-1058
    • Blackwell, L.1    Norris, J.2    Suto, C.M.3    Janzen, W.P.4
  • 46
    • 77249087051 scopus 로고    scopus 로고
    • Chemical phylogenetics of histone deacetylases
    • Bradner JE, West N, Grachan ML, et al. Chemical phylogenetics of histone deacetylases. Nat Chem Biol. 2010;6(3):238-243.
    • (2010) Nat Chem Biol , vol.6 , Issue.3 , pp. 238-243
    • Bradner, J.E.1    West, N.2    Grachan, M.L.3
  • 47
    • 12044258531 scopus 로고
    • Butyrate-induced reactivation of the fetal globin genes: A molecular treatment for the beta-hemoglobinopathies
    • Perrine SP, Faller DV. Butyrate-induced reactivation of the fetal globin genes: a molecular treatment for the beta-hemoglobinopathies. Experientia. 1993;49(2):133-137. (Pubitemid 23063413)
    • (1993) Experientia , vol.49 , Issue.2 , pp. 133-137
    • Perrine, S.P.1    Faller, D.V.2
  • 48
    • 0031660978 scopus 로고    scopus 로고
    • Epstein-barr virus contributes to the malignant phenotype and to apoptosis resistance in Burkitt's lymphoma cell line Akata
    • Komano J, Sugiura M, Takada K. Epstein-Barr virus contributes to the malignant phenotype and to apoptosis resistance in Burkitt's lymphoma cell line Akata. J Virol. 1998;72(11):9150-9156. (Pubitemid 28471860)
    • (1998) Journal of Virology , vol.72 , Issue.11 , pp. 9150-9156
    • Komano, J.1    Sugiura, M.2    Takada, K.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.